TNF Pharmaceuticals Financials
This page shows TNF Pharmaceuticals (TNFA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
TNF Pharmaceuticals' external financing remains the dominant business mechanic because cash burn persists despite narrower operating losses.
From FY2023 to FY2025, operating loss improved from-$17.1M to-$9.8M , but operating cash outflow only improved from-$13.0M to-$9.1M ; the business became less loss-making on paper faster than it became less cash-consuming. That gap matters because FY2025 cash was only$987K , so near-term funding came mainly from$18.3M of financing inflow, not from internal cash generation.
The better FY2025 current ratio of 3.0x versus 1.4x in FY2024 signals improved short-term liquidity, but that improvement arrived alongside
From FY2022 to FY2025, R&D and SG&A were both cut—R&D from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of TNF Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
TNF Pharmaceuticals carries a low D/E ratio of 0.76, meaning only $0.76 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.
TNF Pharmaceuticals's current ratio of 3.00 indicates adequate short-term liquidity, earning a score of 57/100. The company can meet its near-term obligations, though with limited headroom.
TNF Pharmaceuticals generates a -53.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -238.6% the prior year.
TNF Pharmaceuticals passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, TNF Pharmaceuticals generates $0.78 in operating cash flow (-$9.1M OCF vs -$11.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
TNF Pharmaceuticals reported -$11.6M in net income in fiscal year 2025. This represents an increase of 50.2% from the prior year.
TNF Pharmaceuticals earned $-8.66 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.2% from the prior year.
Cash & Balance Sheet
TNF Pharmaceuticals generated -$10.8M in free cash flow in fiscal year 2025, representing cash available after capex.
TNF Pharmaceuticals held $987K in cash against $0 in long-term debt as of fiscal year 2025.
TNF Pharmaceuticals had 4M shares outstanding in fiscal year 2025. This represents an increase of 12287.8% from the prior year.
Margins & Returns
TNF Pharmaceuticals's ROE was -53.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 185.2 percentage points from the prior year.
Capital Allocation
TNF Pharmaceuticals invested $3.5M in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
TNF Pharmaceuticals invested $1.8M in capex in fiscal year 2025, funding long-term assets and infrastructure.
TNFA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $356K-59.2% | $873K-43.5% | $1.5M | N/A | $708K+76.4% | $401K-66.5% | $1.2M |
| SG&A Expenses | N/A | $968K+8.2% | $894K+6.3% | $842K | N/A | $1.1M+8.2% | $1.0M-4.5% | $1.1M |
| Operating Income | N/A | -$1.8M+4.5% | -$1.9M+24.2% | -$2.5M | N/A | -$1.8M+45.8% | -$3.4M-21.0% | -$2.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$2.8M-56.5% | -$1.8M-59.7% | -$1.1M | N/A | -$1.9M+79.8% | -$9.6M+2.4% | -$9.8M |
| EPS (Diluted) | N/A | $-2.50 | $-0.18+50.0% | $-0.36 | N/A | $-107.62-2270.5% | $-4.54+11.7% | $-5.14 |
TNFA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $41.2M+10.6% | $37.2M+117.1% | $17.2M-8.7% | $18.8M-12.3% | $21.4M-10.9% | $24.0M-8.9% | $26.4M+82.0% | $14.5M |
| Current Assets | $16.6M+48.8% | $11.1M+116.3% | $5.2M-24.0% | $6.8M-28.0% | $9.4M-21.7% | $12.0M-16.2% | $14.4M+483.6% | $2.5M |
| Cash & Equivalents | $987K-85.7% | $6.9M+3226.5% | $208K+183.4% | $73K-57.7% | $173K-85.5% | $1.2M+122.4% | $536K+137.5% | $226K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M |
| Total Liabilities | $16.4M+3.3% | $15.9M+34.0% | $11.9M+17.7% | $10.1M-13.3% | $11.6M+66.4% | $7.0M-73.1% | $26.0M+511.4% | $4.3M |
| Current Liabilities | $5.5M-15.3% | $6.5M+17.7% | $5.6M+12.4% | $4.9M-26.3% | $6.7M-4.1% | $7.0M+20.9% | $5.8M+45.6% | $4.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $21.8M+51.9% | $14.3M+171.4% | $5.3M-39.3% | $8.7M-11.2% | $9.8M-41.6% | $16.8M+17053.9% | $98K-99.0% | $9.9M |
| Retained Earnings | -$144.1M-4.8% | -$137.6M-2.8% | -$133.8M-2.1% | -$131.1M-1.5% | -$129.1M-2.5% | -$126.0M-2.2% | -$123.3M-9.2% | -$113.0M |
TNFA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-175.8% | -$1.2M+43.8% | -$2.1M+21.8% | -$2.6M-24.5% | -$2.1M+12.7% | -$2.4M+8.9% | -$2.7M-51.9% | -$1.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$11.7M-680.6% | -$1.5M-168.0% | $2.2M-13.4% | $2.5M+130.6% | $1.1M-64.3% | $3.1M+128.0% | -$11.0M-1605.6% | $732K |
| Financing Cash Flow | $9.0M | N/A | N/A | N/A | $1 | $0-100.0% | $14.0M+1078.9% | -$1.4M |
| Dividends Paid | N/A | N/A | $309K | N/A | N/A | $68K-89.1% | $625K | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TNFA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -19.6%+14.4pp | -34.0%-21.1pp | -12.9% | N/A | -11.5%+9768.8pp | -9780.3%-9681.7pp | -98.6% |
| Return on Assets | N/A | -7.5%+2.9pp | -10.5%-4.5pp | -6.0% | N/A | -8.0%+28.2pp | -36.3%+31.4pp | -67.6% |
| Current Ratio | 3.00+1.3 | 1.71+0.8 | 0.93-0.4 | 1.37-0.0 | 1.40-0.3 | 1.72-0.8 | 2.48+1.9 | 0.62 |
| Debt-to-Equity | 0.76-0.4 | 1.11-1.1 | 2.25+1.1 | 1.16-0.0 | 1.19+0.8 | 0.42-265.4 | 265.83+265.4 | 0.43 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is TNF Pharmaceuticals profitable?
No, TNF Pharmaceuticals (TNFA) reported a net income of -$11.6M in fiscal year 2025.
What is TNF Pharmaceuticals's return on equity (ROE)?
TNF Pharmaceuticals (TNFA) has a return on equity of -53.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is TNF Pharmaceuticals's free cash flow?
TNF Pharmaceuticals (TNFA) generated -$10.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TNF Pharmaceuticals's operating cash flow?
TNF Pharmaceuticals (TNFA) generated -$9.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are TNF Pharmaceuticals's total assets?
TNF Pharmaceuticals (TNFA) had $41.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TNF Pharmaceuticals's capital expenditures?
TNF Pharmaceuticals (TNFA) invested $1.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TNF Pharmaceuticals spend on research and development?
TNF Pharmaceuticals (TNFA) invested $3.5M in research and development during fiscal year 2025.
What is TNF Pharmaceuticals's current ratio?
TNF Pharmaceuticals (TNFA) had a current ratio of 3.00 as of fiscal year 2025, which is generally considered healthy.
What is TNF Pharmaceuticals's debt-to-equity ratio?
TNF Pharmaceuticals (TNFA) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is TNF Pharmaceuticals's return on assets (ROA)?
TNF Pharmaceuticals (TNFA) had a return on assets of -28.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TNF Pharmaceuticals's cash runway?
Based on fiscal year 2025 data, TNF Pharmaceuticals (TNFA) had $987K in cash against an annual operating cash burn of $9.1M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is TNF Pharmaceuticals's Piotroski F-Score?
TNF Pharmaceuticals (TNFA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TNF Pharmaceuticals's earnings high quality?
TNF Pharmaceuticals (TNFA) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is TNF Pharmaceuticals?
TNF Pharmaceuticals (TNFA) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.